CytoSorbents, Aferetica Launch Organ Perfusion System In Italy

  • CytoSorbents Corporation CTSO and Aferetica srl (Italy) have launched products to remove inflammatory mediators at Italy's European Society of Organ Transplantation Congress.
  • Aferetica's PerLife ex vivo organ perfusion system and CytoSorbents' PerSorb adsorber are based on the CytoSorbents ECOS-300CY sorbent technology.
  • PerLife is a system for an organ transplant that provides both perfusion and purification of the kidney and the liver, following organ retrieval and before organ implantation. 
  • CytoSorbents' PerSorb perfusion cartridge is used to remove inflammatory mediators that can compromise the health and quality of the organs. 
  • Related: CytoSorbents' Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag
  • Price Action: CTSO shares are up 4.08% at $9.44 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!